Mesenchymal Stromal Cells and Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
Osteoarthritis (OA) is one of the most frequent musculoskeletal disorders and represents the main indication for total joint arthroplasty. Multipotent mesenchymal stromal cells (MSCs) can be easily isolated and culture expanded from bone marrow aspirates and provide an excellent source of progenitor cells for cell-based regeneration strategies due to their ex vivo differentiation and proliferation capacity. Although there are hints that MSCs derived from OA patients may exhibit altered function the role of MSCs with respect to disease development and progression of OA is not clearly understood to date. To assess whether advanced-stage OA affects MSCs' suitability for musculoskeletal regenerative therapy, in the present study, we compare proliferation and differentiation potential of MSCs from osteoarthritic versus healthy donors.

Detailed Description
-----------------
Clinical data (range of motion of lower limb joints, sociodemographic score dataset, WOMAC score, EQ-5D score, Harris Hip Score, radiological evaluation (OA group only), routine laboratory parameters, and bone metabolism parameters) Osteogenic, chondrogenic, and adipogenic differentiation is proofed qualitatively by cell staining osteogenic, chondrogenic and adipogenic marker gene expression analysis using quantitative real-time RT-PCR cell-specific alkaline phosphatase (ALP) activity assay large-scale gene expression profile Fluorescence-activated cell sorting (FACS)- CD44, CD105 (SH2; endoglin), CD106 (vascular cell adhesion molecule; VCAM-1), CD166, CD29, CD73 (SH3 and SH4), CD90 (Thy-1), CD117, STRO-1 and Sca-1 [%]

Official Title
-----------------
Proliferation and Osteogenic Differentiation of Bone Marrow-derived Mesenchymal Stromal Cells From Osteoarthritic Versus Healthy Donors

Conditions
-----------------
Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: indication for hip THR primary osteoarthritis of the hip Patient's consent Exclusion Criteria: secondary osteoarthritis of the hip Any malignancies infectious disease rheumatic disease osteoporosis Any additional serious disease complicating the participation in this study

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| osteoarthritic donors<br>pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors | |
| healthy donors<br>age-matched healthy donors | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global Gene expression profile of bone marrow-derived mesenchymal stromal cells from osteoarthritic versus healthy donors |  | after msc isolation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferation |  | variable 2 days up to 21 days after msc cultivation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteoarthritis, mesenchymal stromal cells, proliferation